Table 2. Differences in patient and tumour characteristics between none user, prediagnosis & postdiagnosis and only postdiagnosis users of aspirin or NSAIDs.
| None | Pre and postdiagnosis | Only postdiagnosis | ||
|---|---|---|---|---|
| N (%)a | N (%)a | N (%)a | P-value | |
|
Aspirin use | ||||
| Sex | ||||
| Male | 115 (73.2) | 72 (80.9) | 11 (68.8) | 0.3 |
| Female | 42 (26.8) | 17 (19.1) | 5 (31.2) | |
| Age | ||||
| <60 | 40 (25.5) | 11 (12.4) | 6 (37.5) | 0.005 |
| 60–70 | 45 (28.7) | 20 (22.5) | 5 (31.2) | |
| 70–80 | 42 (26.8) | 42 (47.2) | 5 (31.2) | |
| 80+ | 30 (19.1) | 16 (18.0) | 0 (0.0) | |
| Grade | ||||
| I | 7 (4.5) | 5 (5.6) | 2 (12.5) | 0.7 |
| II | 38 (24.2) | 26 (29.2) | 4 (25.0) | |
| III | 65 (41.4) | 30 (33.7) | 6 (37.5) | |
| Unknown | 47 (29.9) | 28 (31.5) | 4 (25.0) | |
| Stage | ||||
| I | 7 (4.5) | 8 (9.0) | 2 (12.5) | <0.001 |
| II | 12 (7.6) | 20 (22.5) | 6 (37.5) | |
| III | 26 (16.6) | 13 (14.6) | 4 (25.0) | |
| IV | 71 (45.2) | 22 (24.7) | 0 (0.0) | |
| Unknown | 41 (26.1) | 26 (29.2) | 4 (25.0) | |
| Comorbidities | ||||
| At least one | 109 (69.4) | 88 (98.9) | 9 (56.3) | <0.001 |
| Other cancer | 22 (14.0) | 18 (20.2) | 0 (0.0) | 0.08 |
| Lung diseases | 17 (10.8) | 16 (18.0) | 1 (6.3) | 0.2 |
| Digestive diseases | 12 (7.6) | 11 (12.4) | 2 (12.5) | 0.4 |
| Hypertension | 28 (17.8) | 33 (37.1) | 3 (18.8) | 0.004 |
| CVA | 9 (5.7) | 14 (15.7) | 0 (0.0) | 0.02 |
| CVD | 32 (20.4) | 60 (67.4) | 3 (18.8) | <0.001 |
| Diabetes | 15 (9.6) | 22 (24.7) | 1 (6.3) | 0.004 |
|
NSAIDs use | ||||
| Sex | ||||
| Male | 115 (73.2) | 156 (76.5) | 69 (76.4) | 0.7 |
| Female | 42 (26.8) | 48 (23.5) | 25 (26.6) | |
| Age | ||||
| <60 | 40 (25.5) | 78 (38.2) | 29 (30.9) | 0.005 |
| 60–70 | 45 (28.7) | 70 (34.3) | 33 (35.1) | |
| 70–80 | 42 (26.8) | 43 (21.1) | 21 (22.3) | |
| 80+ | 30 (19.1) | 13 (6.4) | 11 (11.7) | |
| Grade | ||||
| I | 7 (4.5) | 12 (5.9) | 2 (2.1) | 0.5 |
| II | 38 (24.2) | 53 (26.0) | 29 (30.9) | |
| III | 65 (41.4) | 83 (40.7) | 31 (33.0) | |
| Unknown | 47 (29.9) | 56 (27.5) | 32 (34.0) | |
| Stage | ||||
| I | 7 (4.5) | 24 (11.8) | 4 (4.3) | <0.001 |
| II | 12 (7.6) | 34 (16.7) | 17 (18.1) | |
| III | 26 (16.6) | 40 (19.6) | 21 (22.3) | |
| IV | 71 (45.2) | 70 (34.3) | 23 (24.5) | |
| Unknown | 41 (26.1) | 36 (17.6) | 29 (30.9) | |
| Comorbidities | ||||
| At least one | 109 (69.4) | 132 (64.7) | 62 (66.0) | 0.6 |
| Other cancer | 22 (14.0) | 31 (15.2) | 15 (16.0) | 0.9 |
| Lung diseases | 17 (10.8) | 25 (12.3) | 13 (13.8) | 0.8 |
| Digestive diseases | 12 (7.6) | 21 (10.3) | 3 (3.2) | 0.1 |
| Hypertension | 28 (17.8) | 43 (21.1) | 15 (16.0) | 0.5 |
| CVA | 9 (5.7) | 4 (2.0) | 3 (3.2) | 0.2 |
| CVD | 32 (20.4) | 44 (21.6) | 17 (18.1) | 0.8 |
| Diabetes | 15 (9.6) | 17 (8.3) | 6 (6.4) | 0.7 |
Abbreviations: CVA=cerebrovascular accident; CVD=cardiovascular disease; NSAIDs=nonsteroidal anti-inflammatory drugs.
a
Data represented here are column percentages within the subgroups.